

Reimbursement Policy

Policy Number: RPLAB049

Policy Title: General Inflammation Testing

Approval Date: Aug. 6, 2026

Effective Date: Dec. 4, 2026

Policy Disclaimer

If a conflict arises between a Reimbursement Policy and any Plan document under which a member is entitled to covered services, the Plan document will govern. If a conflict arises between a reimbursement policy and any provider contract pursuant to which a provider participates in and/or provides covered services to eligible member(s) and/or plans, the provider's contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, Benefit Booklets, Summary Plan Descriptions and other coverage documents. Blue Cross and Blue Shield of Texas may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSTX has full and final discretionary authority for their interpretation and application to the extent provided under any applicable Plan documents.

Providers are responsible for submitting accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology (CPT®) Assistant, Healthcare Common Procedure Coding System, ICD-10-CM and ICD-10-PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare & Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services and procedures billed. Claim submissions are subject to claim review, including but not limited to, any terms of benefit coverage, provider contract language, medical policies and reimbursement policies, as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Description

The plan has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information

For policy regarding the use of C-reactive protein (CRP) as a cardiac biomarker, please see policy RPLAB046 Biomarkers for Myocardial Infarction and Chronic Heart Failure.

For policy regarding the use of C-reactive protein (CRP) as a marker for acute pancreatitis, please see policy RPLAB047 Pancreatic Enzyme Testing for Acute Pancreatitis.

1. Measurement of C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR) **may be reimbursable** for the conditions noted in **Note 1** below.
2. For individuals without a diagnosed or suspected inflammatory condition (see **Note 1**), measurement of erythrocyte sedimentation rate (ESR) **is not reimbursable**.
3. Measurement of CRP and/or ESR during general exam without abnormal findings **is not reimbursable**.

NOTE 1: Coverage of CRP, ESR, CRP or ESR, or both CRP and ESR is designated based on the diagnosed or suspected inflammatory condition. Either conventional or high-sensitivity CRP testing are allowed methods of testing for CRP levels. When either CRP **or** ESR are allowed, CRP is the preferred biomarker. If CRP **and** ESR are ordered at the same time for a condition where CRP **or** ESR are allowed, only CRP will be allowed.

Condition	Test Coverage	Frequency of Testing
Acute and Chronic Urticaria	CRP or ESR	Not specified (NS)
Acute Hematogenous Osteomyelitis (AHO)	CRP	To confirm diagnosis; 2 - 3 days during the early therapeutic course; weekly until normalization (or a clear trend toward normalization is evident)
Acute Phase Inflammation	CRP	NS

Ankylosing Spondylitis	CRP or ESR	Regular interval use in patients with active symptoms
Arthritis	CRP and ESR	1-3 months initially; 6-12 months later
Castleman's Disease	CRP	NS
General Inflammation	CRP	NS
Hodgkin Lymphoma	ESR	Every 3 - 6 months for 1 - 2 years; every 6 - 12 months for the next 3 years; annually thereafter
Irritable Bowel Syndrome	CRP and ESR	During initial assessment to exclude other diagnoses (e.g., inflammatory bowel disease)
Large Vessel Vasculitis (Giant Cell Arteritis, Takayasu Arteritis)	CRP and ESR	To confirm diagnosis; every 1-3 months during the first year; every 3-6 months thereafter
Multisystem Inflammatory Syndrome in Children (MIS-C)	CRP	To establish diagnosis
Nonradiographic Axial Spondyloarthritis	CRP or ESR	Regular interval use in patients with active symptoms
Pediatric Chronic Nonbacterial Osteomyelitis (CNO)	CRP and ESR	To confirm diagnosis for individuals meeting all of the entry criteria (see Note 2)
Periprosthetic Joint Infections (PJI)	CRP and ESR	NS
Polymyalgia Rheumatica	CRP or ESR	At initial diagnosis; every 3 months during long-term steroid therapy
Rheumatoid Arthritis	CRP or ESR	Prior to treatment; every 1-3 months during active disease; annually when disease is inactive
Systemic Lupus Erythematosus	CRP or ESR	At initial assessment; every 1-3 months during active disease; every 6-12 months during stable disease; during pregnancy
T-cell Lymphomas	CRP and ESR	NS

Procedure Codes

The following is not an all-encompassing code list. The inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Code	Description
85651	RBC SED RATE NONAUTOMATED
85652	RBC SED RATE AUTOMATED
86140	C-REACTIVE PROTEIN
86141	C-REACTIVE PROTEIN HS

CPT copyright 2025 American Medical Association (AMA). All rights reserved. CPT is a registered trademark of the AMA.

Centers for Medicare & Medicaid Services. (2026). Healthcare Common Procedure Coding System (HCPCS) Level II.

References

1. Antonelli M. Acute phase reactants. Updated October 23, 2024. <https://www.uptodate.com/contents/acute-phase-reactants>
2. Zhao Y, Oliver MS, Schnabel A, et al. EULAR/ACR classification criteria for paediatric chronic nonbacterial osteomyelitis (CNO). *Annals of the Rheumatic Diseases*. 2025;84(9):1458-1468. doi:10.1016/j.ard.2024.11.006
3. NCCN. NCCN Clinical Practice Guidelines in Oncology - Hodgkin Lymphoma Version 1.2026. https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf
4. Baker JF. Diagnosis and differential diagnosis of rheumatoid arthritis. Updated January 29, 2026. <https://www.uptodate.com/contents/diagnosis-and-differential-diagnosis-of-rheumatoid-arthritis>
5. Salvarani C, Muratore F. Clinical manifestations and diagnosis of polymyalgia rheumatica. Updated June 4, 2025. <https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-polymyalgia-rheumatica>
6. Salvarani C, Muratore F. Clinical manifestations of giant cell arteritis. Updated May 14, 2025. <https://www.uptodate.com/contents/clinical-manifestations-of-giant-cell-arteritis>
7. Gergianaki I, Bertsias G. Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. *Frontiers in Medicine*. 2018;5:161. doi:10.3389/fmed.2018.00161
8. Black S, Kushner I, Samols D. C-reactive Protein. *The Journal of biological chemistry*. 2004;279(47):48487-90. doi:10.1074/jbc.R400025200
9. Wu AH, Lewandrowski K, Gronowski AM, Grenache DG, Sokoll LJ, Magnani B. Antiquated tests within the clinical pathology laboratory. *The American journal of managed care*. 2010;16(9):e220-7. <https://pubmed.ncbi.nlm.nih.gov/21250398/>
10. Horsti J, Rontu R, Collings A. A Comparison Between the StaRRsed Auto-Compact Erythrocyte Sedimentation Rate Instrument and the Westergren Method. *Journal of Clinical Medicine Research*. 2010;2(6):261-265. doi:10.4021/jocmr476w

-
11. Shmerling RH, Greisen SR. Biologic markers in the assessment of rheumatoid arthritis. Updated October 13, 2025. <https://www.uptodate.com/contents/biologic-markers-in-the-assessment-of-rheumatoid-arthritis>
 12. Hale AJ, Ricotta DN, Freed JA. Evaluating the Erythrocyte Sedimentation Rate. *Jama*. 2019;321(14):1404-1405. doi:10.1001/jama.2019.1178
 13. Kratz A, Plebani M, Peng M, Lee YK, McCafferty R, Machin SJ. ICSH recommendations for modified and alternate methods measuring the erythrocyte sedimentation rate. *International Journal of Laboratory Hematology*. 2017;39(5):448-457. doi:10.1111/ijlh.12693
 14. Watson J, Jones HE, Banks J, Whiting P, Salisbury C, Hamilton W. Use of multiple inflammatory marker tests in primary care: using Clinical Practice Research Datalink to evaluate accuracy. *Br J Gen Pract*. 2019;69(684):e462-e469. doi:10.3399/bjgp19X704309
 15. Sherkatolabbasieh H, Firouzi M, Shafizadeh S. Evaluation of platelet count, erythrocyte sedimentation rate and C-reactive protein levels in paediatric patients with inflammatory and infectious disease. *New Microbes and New Infections*. 2020;37:100725. doi:10.1016/j.nmni.2020.100725
 16. Alende-Castro V, Alonso-Sampedro M, Fernández-Merino C, et al. C-Reactive Protein versus Erythrocyte Sedimentation Rate: Implications Among Patients with No Known Inflammatory Conditions. *J Am Board Fam Med*. 2021;34(5):974-983. doi:10.3122/jabfm.2021.05.210072
 17. Crowson CS, Rahman MU, Matteson EL. Which Measure of Inflammation to Use? A Comparison of Erythrocyte Sedimentation Rate and C-Reactive Protein Measurements from Randomized Clinical Trials of Golimumab in Rheumatoid Arthritis. 10.3899/jrheum.081188. *The Journal of Rheumatology*. 2009;36(8):1606. doi:10.3899/jrheum.081188
 18. Nielung L, Christensen R, Danneskiold-Samsøe B, et al. Validity and Agreement between the 28-Joint Disease Activity Score Based on C-Reactive Protein and Erythrocyte Sedimentation Rate in Patients with Rheumatoid Arthritis. *Arthritis*. 2015;2015:401690. doi:10.1155/2015/401690
 19. Fransen J, van Riel PL. DAS remission cut points. *Clinical and experimental rheumatology*. 2006;24(6 Suppl 43):S-29-32.
 20. Hensor EMA, Emery P, Bingham SJ, Conaghan PG. Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): can they be reduced? *Rheumatology*. 2010;49(8):1521-1529. doi:10.1093/rheumatology/keq117
 21. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. *Arthritis Care & Research*. 2012;64(5):640-647. doi:10.1002/acr.21649
 22. Bitik B, Mercan R, Tufan A, et al. Differential diagnosis of elevated erythrocyte sedimentation rate and C-reactive protein levels: a rheumatology perspective. *European Journal of Rheumatology*. 2015;2(4):131-134. doi:10.5152/eurjrheum.2015.0113
 23. McCarthy EM, MacMullan PA, Al-Mudhaffer S, et al. Plasma Fibrinogen Along with Patient-reported Outcome Measures Enhances Management of Polymyalgia Rheumatica: A Prospective Study. 10.3899/jrheum.131055. *The Journal of Rheumatology*. 2014;41(5):931. doi:10.3899/jrheum.131055

-
24. Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. *Arthritis Care & Research*. 2008;59(12):1814-1820. doi:10.1002/art.24316
 25. Gordon C, Amissah-Arthur M-B, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. *Rheumatology*. 2018;57(1):e1-e45. doi:10.1093/rheumatology/kex286
 26. Baddour LM, Chen AF. Prosthetic joint infection: Epidemiology, microbiology, clinical manifestations, and diagnosis. Updated March 23, 2026. <https://www.uptodate.com/contents/prosthetic-joint-infection-epidemiology-microbiology-clinical-manifestations-and-diagnosis>
 27. Perez-Prieto D, Portillo ME, Puig-Verdie L, et al. C-reactive protein may misdiagnose prosthetic joint infections, particularly chronic and low-grade infections. *International orthopaedics*. 2017;41(7):1315-1319. doi:10.1007/s00264-017-3430-5
 28. Kheir MM, Tan TL, Shohat N, Foltz C, Parvizi J. Routine Diagnostic Tests for Periprosthetic Joint Infection Demonstrate a High False-Negative Rate and Are Influenced by the Infecting Organism. *The Journal of bone and joint surgery American volume*. 2018;100(23):2057-2065. doi:10.2106/jbjs.17.01429
 29. Christopher ZK, McQuivey KS, Deckey DG, Haglin J, Spangehl MJ, Bingham JS. Acute or chronic periprosthetic joint infection? Using the ESR / CRP ratio to aid in determining the acuity of periprosthetic joint infections. *J Bone Jt Infect*. 2021;6(6):229-234. doi:10.5194/jbji-6-229-2021
 30. Clough J, Colwill M, Poullis A, Pollok R, Patel K, Honap S. Biomarkers in inflammatory bowel disease: a practical guide. *Therapeutic Advances in Gastroenterology*. 2024;17:17562848241251600. doi:10.1177/17562848241251600
 31. Muresan S, Slevin M. C-reactive Protein: An Inflammatory Biomarker and a Predictor of Neurodegenerative Disease in Patients With Inflammatory Bowel Disease? *Cureus*. 2024;16(4)doi:10.7759/cureus.59009
 32. WHO. Second WHO Model List of Essential In Vitro Diagnostics. <https://www.who.int/docs/default-source/nutritionlibrary/complementary-feeding/second-who-model-list-v8-2019.pdf>
 33. WHO. The selection and use of essential in vitro diagnostics. <https://iris.who.int/server/api/core/bitstreams/69fa4fa6-8830-4e00-a6fc-63257b677f65/content>
 34. NCCN. NCCN Clinical Practice Guidelines in Oncology - Castleman Disease Version 2.2026. https://www.nccn.org/professionals/physician_gls/pdf/castleman.pdf
 35. NCCN. NCCN Clinical Practice Guidelines in Oncology - T-Cell Lymphomas Version 2.2026. https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf
 36. ASCP. Thirty Five Things Physicians and Patients Should Question. Updated September 1, 2020. https://ascpcontentwebsite.blob.core.windows.net/content/docs/default-source/istp/cw_35recommendations.pdf
 37. Melgar M, Lee EH, Miller AD, et al. Council of State and Territorial Epidemiologists/CDC Surveillance Case Definition for Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 Infection - United States. *MMWR Recomm Rep*. Dec 16 2022;71(4):1-14. doi:10.15585/mmwr.rr7104a1

-
38. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. 10.1136/ard.2008.088351. *Annals of the Rheumatic Diseases*. 2009;68(3):318. doi:10.1136/ard.2008.088351
 39. Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. *Annals of the Rheumatic Diseases*. 2020;79(1):19-30. doi:10.1136/annrheumdis-2019-215672
 40. Colebatch AN, Edwards CJ, Østergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. 10.1136/annrheumdis-2012-203158. *Annals of the Rheumatic Diseases*. 2013;72(6):804. doi:10.1136/annrheumdis-2012-203158
 41. DeJaco C, Singh Yogesh P, Perel P, et al. 2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. *Arthritis & Rheumatology*. 2015;67(10):2569-2580. doi:10.1002/art.39333
 42. Combe B, Landewe R, Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. 10.1136/annrheumdis-2016-210602. *Annals of the Rheumatic Diseases*. 2017;76(6):948. doi:10.1136/annrheumdis-2016-210602
 43. DeJaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. 10.1136/annrheumdis-2017-212649. *Annals of the Rheumatic Diseases*. 2018;77(5):636. doi:10.1136/annrheumdis-2017-212649
 44. DeJaco C, Ramiro S, Bond M, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. *Ann Rheum Dis*. May 15 2024;83(6):741-751. doi:10.1136/ard-2023-224543
 45. van Steenbergen HW, Doornkamp F, Alivernini S, et al. EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia. *Annals of the Rheumatic Diseases*. 2025;84(9):1445-1457. doi:10.1016/j.ard.2025.01.021
 46. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. Jul 2021;73(7):924-939. doi:10.1002/acr.24596
 47. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis & rheumatology (Hoboken, NJ)*. 2016;68(2):282-298. doi:10.1002/art.39298
 48. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Care Res (Hoboken)*. 2019;71(10):1285-1299. doi:10.1002/acr.24025
 49. England BR, Tjong BK, Bergman MJ, et al. 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. *Arthritis Care Res (Hoboken)*. 2019;71(12):1540-1555. doi:10.1002/acr.24042
 50. Arnold MJ. Management of Rheumatoid Arthritis: Update From ACR. <https://www.aafp.org/afp/2022/0900/practice-guidelines-rheumatoid-arthritis.pdf>

-
51. Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. *Arthritis Rheumatol*. 2021;73(8):1349-1365. doi:10.1002/art.41774
 52. Caylor TL, Perkins A. Recognition and management of polymyalgia rheumatica and giant cell arteritis. *Am Fam Physician*. 2013;88(10):676-84.
 53. Raleigh MF, Stoddard J, Darrow HJ. Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review. *Am Fam Physician*. 2022;106(4):420-426.
 54. Ha CS, Hodgson DC, Advani R, et al. Follow-up of Hodgkin lymphoma. *American College of Radiology ACR Appropriateness Criteria*. 2014;
 55. Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. *Rheumatology (Oxford, England)*. 2010;49(8):1594-7. doi:10.1093/rheumatology/keq039a
 56. Dasgupta B. Concise guidance: diagnosis and management of giant cell arteritis. *Clinical medicine (London, England)*. 2010;10(4):381-6. doi:10.7861/clinmedicine.10-4-381
 57. Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. *Rheumatology (Oxford, England)*. 2010;49(1):186-90. doi:10.1093/rheumatology/kep303a
 58. Toyoda T, Armitstead Z, Bhide S, et al. Treatment of polymyalgia rheumatica: British Society for Rheumatology guideline scope. *Rheumatology Advances in Practice*. 2024;8(1)doi:10.1093/rap/rkae002
 59. Mackie SL, Dejaco C, Appenzeller S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. *Rheumatology (Oxford, England)*. 2020;59(3):e1-e23. doi:10.1093/rheumatology/kez672
 60. Hazlewood GS, Pardo JP, Barnabe C, et al. Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs. *The Journal of Rheumatology*. 2022:jrheum.220209. doi:10.3899/jrheum.220209
 61. Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, et al. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. *J Rheumatol*. 2018;45(10):1426-1439. doi:10.3899/jrheum.171459
 62. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. *The Journal of allergy and clinical immunology*. 2014;133(5):1270-7. doi:10.1016/j.jaci.2014.02.036
 63. NICE. Irritable bowel syndrome in adults: diagnosis and management. National Institute for Health and Care Excellence. <https://www.nice.org.uk/guidance/cg61/resources/irritable-bowel-syndrome-in-adults-diagnosis-and-management-pdf-975562917829>
 64. NICE. Rheumatoid arthritis in adults: diagnosis and management. *National Institute for Health and Care Excellence: Clinical Guidelines*. 2018. *National Institute for Health and Care Excellence: Guidelines*.
 65. Smalley W, Falck-Ytter C, Carrasco-Labra A, Wani S, Lytvyn L, Falck-Ytter Y. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). *Gastroenterology*. 2019;157(3):851-854. doi:10.1053/j.gastro.2019.07.004

66. AAOS. Evidence-Based Clinical Practice Guideline for Diagnosis and Prevention of Periprosthetic Joint Infections. Updated March 11, 2019.
<https://www.aaos.org/globalassets/quality-and-practice-resources/pji/pji-clinical-practice-guideline-final-2-17-21.pdf>
67. Woods CR, Bradley JS, Chatterjee A, et al. Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics. *J Pediatric Infect Dis Soc.* 2021;10(8):801-844. doi:10.1093/jpids/piab027
68. Government of British Columbia. C-Reactive Protein and Erythrocyte Sedimentation Rate Testing. Updated December 5, 2018.
<https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/esr#seventeen>
69. FDA. Review Criteria for Assessment of C-Reactive Protein (CRP), High Sensitivity C-Reactive Protein (hsCRP) and Cardiac C-Reactive Assays.
<https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidanc edocuments/ucm071017.pdf>

Policy History

Approval Date	Description
08/06/2026	12/4/2026; Document updated. The following changes were made to Reimbursement Information: Revised #2 for clarity. For the table (now Note 1), added CRP recommendation for Multisystem Inflammatory Syndrome in Children (MIS-C); added CRP and ESR recommendation for Pediatric Chronic Nonbacterial Osteomyelitis (CNO) and Note 2 with entry criteria for CNO. Changed “Test Preference” in Note 1 to “Test Coverage” for clarity. References revised.
7/25/2025	11/7/2025; Document updated with literature review. The following changes were made to Reimbursement Information: Added Note 1 referencing CPCPLAB046 for the use of CRP as a cardiac biomarker, and CPCPLAB047 for the use of CRP as a marker for acute pancreatitis. Removed “inflammatory” from #1 as some conditions listed in Table 1 are noninflammatory, with measurement of CRP/ESR used to differentiate between a noninflammatory and inflammatory condition. Revised Table 1 introduction to read: Coverage of CRP, ESR, CRP or ESR, or both CRP and ESR is designated based on the diagnosed or suspected inflammatory condition. Either conventional or high-sensitivity CRP testing are allowed methods of testing for CRP levels. When either CRP or ESR are allowed, CRP is the preferred biomarker. If CRP and ESR are ordered at the same time for a condition where CRP or ESR are allowed, only CRP

	will be allowed. Within Table 1, added "(e.g., inflammatory bowel disease) in the Frequency of Testing column for Irritable Bowel Syndrome; deleted row specific to Giant Cell Arteritis; under Large Vessel Vasculitis, added Giant Cell Arteritis and Takayasu Arteritis; changed Test Preference for that indication to CRP and ESR; added "To confirm diagnosis; every 1-3 months during the first year; every 3-6 months thereafter" to the Frequency of Testing for that indication. Added code 86141. References revised.
09/13/2024	01/01/2025: New policy.